Summary
Quanterix has developed a simple blood test to aid in the detection of traumatic brain injury. Using its Simoa technology, Quanterix is able to measure molecular signatures (biomarkers) of brain injury in blood.
Quanterix is working to detect and quantify mild to moderate traumatic brain injury almost immediately after the injury has taken place, which will help to better predict the long-term prognosis of individuals who have undergone acute and repetitive injuries. Quanterix’s goal is to provide a blood test that speeds the diagnosis of a concussion in a clinical setting and on the sidelines in a sports arena.
